GSK registers 5% Growth

General Medicine grows 5% and Vaccines 10% led by Shingrix

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 30th September 2023. Revenue from Operations for the quarter came in at Rs 953 crores recording a growth of 5%. PBT for the quarter at Rs 297 crores recorded a growth of 13% with EBITDA margins at 30.1%.

Revenue from Operations for the half year ended 30th September 2023 at Rs 1691 crores recorded a growth of 3%. PBT for the half year at Rs 458 crores improved 9% with EBITDA margins at 25.3%.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "Our Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held leadership position for our key brands in relevant therapy areas such as anti-infectives and dermatology.

Our focus in the coming quarters will remain on strong volume led performance in General Medicines and Paediatric vaccines. We will also explore innovative solutions using Omnichannel strategy to expand our reach and coverage to our target segments. We continue to drive the expansion of the adult immunisation category with Shingrix (Zoster Vaccine Recombinant, Adjuvanted).”

About GlaxoSmithKline Pharmaceuticals Limited (GSK)

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit

Media Contact

Ransom D' Souza -

Communications & Government Affairs